MSP104

**MSP104** is a pipeline drug candidate developed by **Methapharm**, a specialty pharmaceutical company focused on respiratory and allergy products. Categorized within the **Allergy** therapeutic area, MSP104 is part of a series of internal projects (including MSP101, MSP103, and MSP105) aimed at expanding the company's portfolio of diagnostic and therapeutic agents. As of early 2024, the specific active ingredient, molecular target, and modality (e.g., small molecule or biologic) have not been publicly disclosed. The company has indicated a target launch date of **2024**, which typically implies that the product is undergoing regulatory review or is in the final stages of commercial preparation. Methapharm's existing expertise in products like Methacholine (Provocholine) suggests MSP104 may be a niche therapeutic or a diagnostic tool for allergic sensitivities.